Gil Letort

Gil Letort is a Research Associate at Cellectis since February 2020, focusing on the development of a novel gene therapy for sickle cell anemia utilizing Talen technology. Prior to this role, Gil worked in the INSERM UMR-1131 unit from March 2014 to February 2020 as an Ingenieur, engaging in research on myeloid hemopathies linked to genetic mutations in hematopoietic stem cells. Earlier experience includes an internship at Cellectis in 2013, where Gil was involved in iPS cell engineering, and a research internship at INSERM UMR 747 in 2012 that examined oxidative stress in cells deficient in VLCAD. Education includes a Master 2 in R&D Biotechnology and a Master 1 in Molecular Biology from Pierre and Marie Curie University, along with a Bachelor's degree in Biochemistry and Molecular Biology from Nantes Université.